Arcellx Inc.

37 articles with Arcellx Inc.

• Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference

  2/21/2023

  Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023, at 1:00 p.m. ET.

• Arcellx to Participate in Upcoming Investor Conferences - February 02, 2023

  2/2/2023

  Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the company's participation in the following investor conferences.

• Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

  12/9/2022

  Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.

• Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

  12/9/2022

  Arcellx, Inc. today announced continued robust long-term responses from its CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma, dosing of first patients in its iMMagine.

• Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

  12/9/2022

  Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. 

• Arcellx Reports Third Quarter 2022 Financial Results and Business Progress

  11/14/2022

  Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the third quarter ended September 30, 2022.

• Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition

  11/3/2022

  Arcellx, Inc. (NASDAQ: ACLX) today announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022, in New Orleans, Louisiana.

• Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference

  9/7/2022

  Arcellx, Inc. (NASDAQ: ACLX), today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 3:30 p.m. ET.

• Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results

  8/15/2022

  Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2022.

• Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

  6/21/2022

  Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of its upsized public offering of 8,050,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares of common stock, at a price to the public of $16.00 per share.

• Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

  6/21/2022

  Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel.

• Arcellx Announces Upsizing and Pricing of Follow-On Public Offering

  6/16/2022

  Arcellx, Inc. announced the pricing of an upsized underwritten follow-on offering of 7,000,000 shares of common stock at a price to the public of $16.00 per share.

• Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting

  6/3/2022

  Arcellx, Inc. (NASDAQ: ACLX), today announced new positive clinical data from the ongoing Phase 1 expansion study of its novel, autologous, CART-ddBCMA therapy for the treatment of patients with relapsed or refractory multiple myeloma.

• Arcellx Appoints Michelle Gilson as Chief Financial Officer

  5/23/2022

  Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer.

• Arcellx Appoints Olivia Ware to Board of Directors

  5/16/2022

  Arcellx, Inc. announced the appointment of Olivia Ware to its Board of Directors.

• Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results

  5/12/2022

  Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported business highlights and financial results for the first quarter ended March 31, 2022.

• Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

  5/10/2022

  Arcellx, Inc. announced that the first patient has been dosed in its open-label, multicenter ACLX-001 Phase 1 clinical trial to evaluate the company's novel ARC-SparX program in patients with relapsed or refractory multiple myeloma.

• Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

  5/9/2022

  Arcellx, Inc. (NASDAQ: ACLX), today announced the publication of clinical data from its dose escalation cohorts in its ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma (r/r MM).

• Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference

  5/5/2022

  Arcellx, Inc. announced that management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 5:00 p.m. E.T.

• Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

  4/27/2022

  Arcellx, Inc. announced that new clinical data from its Phase 1 Study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented in an oral abstract session at the 2022 ASCO Annual Meeting taking place June 3-7, 2022, in Chicago, Illinois.